Exelixis (NASDAQ: EXEL) reported first-quarter earnings, posting something many biotechs never achieve: profitability on an operating basis.
Metric
Q1 2017
Exelixis (NASDAQ: EXEL) reported first-quarter earnings, posting something many biotechs never achieve: profitability on an operating basis.
Metric
Q1 2017